Herold Advisors Inc. Has $2.42 Million Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Herold Advisors Inc. increased its holdings in Zoetis Inc. (NYSE:ZTSGet Rating) by 2.7% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 14,093 shares of the company’s stock after purchasing an additional 373 shares during the period. Zoetis makes up 1.1% of Herold Advisors Inc.’s portfolio, making the stock its 22nd biggest position. Herold Advisors Inc.’s holdings in Zoetis were worth $2,422,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in ZTS. BlackRock Inc. increased its holdings in shares of Zoetis by 3.6% during the first quarter. BlackRock Inc. now owns 41,766,559 shares of the company’s stock worth $7,876,755,000 after buying an additional 1,450,749 shares in the last quarter. State Street Corp increased its holdings in shares of Zoetis by 2.7% during the fourth quarter. State Street Corp now owns 19,994,627 shares of the company’s stock worth $4,879,289,000 after buying an additional 529,974 shares in the last quarter. Alliancebernstein L.P. increased its holdings in shares of Zoetis by 2.6% during the fourth quarter. Alliancebernstein L.P. now owns 17,663,325 shares of the company’s stock worth $4,310,381,000 after buying an additional 441,440 shares in the last quarter. Bank of America Corp DE increased its holdings in shares of Zoetis by 0.6% during the first quarter. Bank of America Corp DE now owns 12,775,847 shares of the company’s stock worth $2,409,397,000 after buying an additional 78,088 shares in the last quarter. Finally, Wellington Management Group LLP increased its holdings in shares of Zoetis by 24.4% during the first quarter. Wellington Management Group LLP now owns 6,301,310 shares of the company’s stock worth $1,188,364,000 after buying an additional 1,234,738 shares in the last quarter. Institutional investors and hedge funds own 91.05% of the company’s stock.

Insiders Place Their Bets

In other Zoetis news, EVP Roxanne Lagano sold 2,167 shares of the stock in a transaction on Friday, July 22nd. The shares were sold at an average price of $180.26, for a total value of $390,623.42. Following the sale, the executive vice president now directly owns 23,687 shares in the company, valued at $4,269,818.62. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, CEO Kristin C. Peck sold 9,689 shares of the firm’s stock in a transaction on Thursday, July 21st. The shares were sold at an average price of $180.00, for a total transaction of $1,744,020.00. Following the sale, the chief executive officer now directly owns 39,743 shares in the company, valued at $7,153,740. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Roxanne Lagano sold 2,167 shares of the firm’s stock in a transaction on Friday, July 22nd. The stock was sold at an average price of $180.26, for a total transaction of $390,623.42. Following the sale, the executive vice president now owns 23,687 shares in the company, valued at $4,269,818.62. The disclosure for this sale can be found here. Over the last three months, insiders have sold 16,501 shares of company stock worth $2,949,073. Company insiders own 0.12% of the company’s stock.

Zoetis Trading Up 0.4 %

ZTS stock traded up $0.59 during midday trading on Friday, reaching $150.05. The company’s stock had a trading volume of 1,623,978 shares, compared to its average volume of 2,150,557. Zoetis Inc. has a 52 week low of $147.86 and a 52 week high of $249.27. The stock has a market cap of $70.24 billion, a PE ratio of 33.92, a price-to-earnings-growth ratio of 2.64 and a beta of 0.77. The company has a quick ratio of 1.46, a current ratio of 2.18 and a debt-to-equity ratio of 1.14. The business’s 50-day simple moving average is $167.61 and its 200-day simple moving average is $173.54.

Zoetis (NYSE:ZTSGet Rating) last announced its quarterly earnings data on Thursday, August 4th. The company reported $1.20 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.22 by ($0.02). Zoetis had a net margin of 26.14% and a return on equity of 49.03%. The business had revenue of $2.10 billion during the quarter, compared to the consensus estimate of $2.03 billion. During the same period in the previous year, the business posted $1.19 earnings per share. Zoetis’s revenue was up 7.8% compared to the same quarter last year. As a group, sell-side analysts expect that Zoetis Inc. will post 5.01 EPS for the current year.

Analyst Ratings Changes

ZTS has been the subject of several recent analyst reports. Piper Sandler initiated coverage on shares of Zoetis in a report on Monday, July 11th. They set an “overweight” rating and a $205.00 price objective for the company. William Blair reissued an “outperform” rating on shares of Zoetis in a research note on Friday, August 5th. StockNews.com cut shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday. The Goldman Sachs Group decreased their price target on shares of Zoetis from $208.00 to $202.00 and set a “buy” rating on the stock in a research note on Thursday, July 21st. Finally, Stifel Nicolaus decreased their price target on shares of Zoetis from $275.00 to $225.00 and set a “buy” rating on the stock in a research note on Friday, June 24th. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, Zoetis currently has a consensus rating of “Moderate Buy” and a consensus price target of $224.00.

Zoetis Profile

(Get Rating)

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.

See Also

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.